Replies to post #137136 on Biotech Values

[acgood]

ISIS was working on PTP1b inhibitor, but has abandoned that program. Also has glucagon receptor (GCGR) and glucocortocoid receptor (GCCR) programs in phase 1 directed at diabetes.
http://goo.gl/QZ4TB

[genisi]

Diabetes treatments with new methods of action

TAK-875 - a GPR40 agonist is in phase III trials:

http://www.takeda.com/press/article_43205.html

There are several glucokinase activators in clinical trials (think that AZD1656 is the most advanced now after LLY terminated and Roch is on hold).